Galectin Therapeutics Inc (OQ:GALT)

Business Focus: Biotechnology & Medical Research

Sep 29, 2020 12:00 pm ET
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host an investor conference call and webinar to discuss the Company’s NASH-RX clinical trial and to...
Sep 22, 2020 08:04 am ET
Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will host an investor conference call and webinar to discuss the Company’s NASH-RX clinical trial and to...
Sep 10, 2020 08:00 am ET
Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference, on Monday,...
Sep 02, 2020 08:00 am ET
Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of current board member, Joel Lewis, to the position of Chief Executive Officer (CEO) and President. In...
Aug 10, 2020 08:00 am ET
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2020. These results are included in the...
Jun 30, 2020 08:00 am ET
Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins, announced today that it has enrolled its first patients in the NASH-RX trial. NASH-RX is an international, seamless, adaptively-designed Phase 2b/3 trial of...
May 11, 2020 08:00 am ET
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2020. These results are included in the...
Apr 30, 2020 09:00 am ET
Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) its protocol for a seamless adaptively-designed...
Apr 02, 2020 08:04 am ET
Galectin Therapeutics Update on the Impact of COVID-19
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities. As the global...
Mar 16, 2020 08:00 am ET
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2019. These results are included in the...
Feb 20, 2020 08:00 am ET
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced the appointment of Pol F. Boudes, M.D. to the position of Chief Medical Officer.  In this position, Dr. Boudes will oversee Galectin’s global...
Feb 04, 2020 08:00 am ET
Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the 3rd Global NASH Congress 2020 at the...
Dec 09, 2019 08:00 am ET
Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial in NASH cirrhosis have been published in the...
Dec 05, 2019 12:06 pm ET
Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, recently presented its current plans for an Adaptively Designed Phase 3 clinical trial (NASH-RX) of its lead compound, belapectin...
Nov 26, 2019 08:00 am ET
Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H. Shlevin, Ph.D., president and chief executive officer, will present a corporate update via live webcast...
Nov 18, 2019 04:10 pm ET
Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer, Ph.D., Vice President, Discovery Research and Product Development for Galectin Therapeutics, will be...
Nov 12, 2019 08:00 am ET
Galectin Therapeutics Reports Q3 2019 Financial Results
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2019. These results are...
Nov 11, 2019 09:47 am ET
Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic...
Nov 05, 2019 08:00 am ET
Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in subsequent ad hoc analysis of Galectin Therapeutics’ NASH-CX Phase 2...
Sep 17, 2019 08:00 am ET
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have received notice of issuance of U.S. Patent Number 10,398,778 titled "Method...
Aug 09, 2019 08:00 am ET
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2019. These results are included in...
Aug 05, 2019 08:05 am ET
Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for assessment the Phase 3 protocol for using belapectin (GR-MD-02) for the treatment of compensated...
May 28, 2019 09:05 am ET
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering has closed.  The Rights Offering resulted in the issuance of approximately 10.4 million shares...
May 23, 2019 05:30 pm ET
Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price (i.e., the final computed price) of the common stock and related warrant subscribed in its Rights...
May 10, 2019 08:05 am ET
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein.  The letter reads as follows: Dear...
May 10, 2019 08:00 am ET
Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2019. These results are included in...
Apr 16, 2019 07:55 am ET
New Research Coverage Highlights The Wendy's, Galectin Therapeutics, LSC Communications, RadNet, ArcBest, and EnPro Industries — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of The Wendy's Company (NASDAQ:WEN), Galectin Therapeutics Inc....
Apr 15, 2019 08:00 am ET
Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key dates and pricing structure for its previously announced rights offering of approximately 14 million...
Apr 02, 2019 08:00 am ET
Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright Global...
Mar 22, 2019 10:19 am ET
Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination...
Mar 06, 2019 08:03 am ET
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein.  The letter reads as follows: Dear...
Mar 06, 2019 08:02 am ET
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) (available at www.sec.gov)...
Mar 06, 2019 08:00 am ET
Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2018. These results are included in the Company's Annual Report on Form...
Feb 26, 2019 07:25 am ET
Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Infinera Corporation (NASDAQ:INFN), Alliant Energy Corporation...
Feb 25, 2019 08:00 am ET
Galectin Therapeutics to Present at Berenberg NASH Day in New York
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at Berenberg NASH Day at the Berenberg Offices...
Jan 15, 2019 08:00 am ET
Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest institutional shareholder, 10X Fund L.P., has converted all of its Series B Convertible Preferred Stock...
Dec 20, 2018 08:30 am ET
Galectin Therapeutics Announces Extension of $10 Million Line Credit
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of credit entered into on December 19, 2017, has been extended by one year for both...
Nov 27, 2018 08:15 am ET
New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initi
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Martin Midstream Partners L.P. (NASDAQ:MMLP), Galectin Therapeutics...
Nov 19, 2018 09:19 am ET
Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the 2nd Annual Anti-Fibrotic Drug...
Nov 13, 2018 08:00 am ET
Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its third fiscal quarter, which ended September 30, 2018, and provided a business update. These...
Nov 05, 2018 08:00 am ET
Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in Galectin Therapeutics’ NASH-CX Phase 2 Clinical Trial has been accepted for...
Oct 15, 2018 10:22 am ET
Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the upcoming ROTH Capital Battle of the NASH Thrones Investor Conference being held...
Oct 15, 2018 08:00 am ET
Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the upcoming ROTH Capital Battle of the NASH Thrones Investor Conference being held...
Oct 11, 2018 07:30 am ET
Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Altra Industrial Motion Corp. (NASDAQ:AIMC), IDEXX Laboratories, Inc....
Sep 20, 2018 08:00 am ET
Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced additional preliminary clinical data from cohort 3 of an investigator-initiated Phase 1b...
Aug 28, 2018 08:30 am ET
Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s President and CEO, will present at the H.C. Wainwright 20th Global Investment...
Aug 14, 2018 08:00 am ET
Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its second fiscal quarter, which ended June 30, 2018, and provided a business update. These results...
Aug 03, 2018 07:30 am ET
Market Trends Toward New Normal in Conn's, Herman Miller, TrueBlue, Brandywine Realty Trust, Tenneco, and Galectin Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conn's, Inc. (NASDAQ:CONN), Herman Miller, Inc. (NASDAQ:MLHR), TrueBlue,...
Jun 27, 2018 08:00 am ET
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631  titled...
Jun 22, 2018 10:40 am ET
Company Profile for Galectin Therapeutics Inc.
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, a more advanced form of NASH-related fibrosis. This is one of the most common liver diseases and is believed to be amongst the largest drug developm
Jun 12, 2018 08:32 am ET
Galectin Therapeutics Inc. Announces New CEO
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin, Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive...
Jun 04, 2018 09:00 am ET
Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors elected Richard E. Uihlein as Chairman of the Board of Directors. Additionally, Kevin D. Freeman was...
May 14, 2018 09:05 am ET
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH...
May 11, 2018 04:10 pm ET
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2018, and provided a business update. These results are included in...
Apr 26, 2018 07:55 am ET
Recent Analysis Shows Alphabet, Northrop Grumman, HomeStreet, Galectin Therapeutics, AZZ, and Restoration Robotics Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alphabet Inc. (NASDAQ:GOOGL), Northrop Grumman Corporation...
Apr 18, 2018 08:00 am ET
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, has been selected as an...
Apr 16, 2018 08:00 am ET
Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
NORCROSS, Ga., April 16, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today provided highlights from a late-breaker oral presentation at The International Liver Congress™ 2018, European Association for the...
Apr 04, 2018 09:00 am ET
Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
GR-MD-02 treatment in NASH cirrhosis patients without esophageal varices shows statistically significant and clinically meaningful effects
Apr 02, 2018 10:20 am ET
Mar 29, 2018 08:10 am ET
Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
NORCROSS, Ga., March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2017. These results are included in the...
Mar 09, 2018 08:30 am ET
Galectin Therapeutics to Present at Two International Conferences in March
NORCROSS, Ga., March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, will participate in two upcoming international ...
Mar 08, 2018 08:30 am ET
Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
NORCROSS, Ga., March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin, the Company’s Chief Operating Officer, will present at the 2nd Annual H.C....
Mar 05, 2018 04:00 pm ET
Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018
NORCROSS, Ga., March 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be...
Feb 28, 2018 04:35 pm ET
Galectin Therapeutics to Present at 30th Annual ROTH Conference
NORCROSS, Ga., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, will present at the 30th Annual...
Feb 16, 2018 08:00 am ET
Recent Analysis Shows SBA Communications, AMAG Pharmaceuticals, Galectin Therapeutics, Xilinx, J.B. Hunt Transport Services, and Southern Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SBA Communications Corporation (NASDAQ:SBAC), AMAG Pharmaceuticals,...
Feb 06, 2018 09:15 am ET
Galectin Therapeutics to Present at BIO CEO & Investor Conference
NORCROSS, Ga., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s CEO and CMO, will present at BIO CEO &...
Jan 25, 2018 08:30 am ET
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
The broad protection of these patents opens doors to partnerships in the world’s second- and third-largest pharmaceutical markets
Dec 19, 2017 04:10 pm ET
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
NORCROSS, Ga., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured line of credit facility with stockholder and new director...
Dec 18, 2017 11:01 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Galectin Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Galectin Therapeutics, Inc. (NASDAQ:GALT) concerning possible breaches of fiduciary duty. To obtain additional information, go to:
Dec 18, 2017 08:59 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Galectin Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, Dec. 18, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Galectin Therapeutics Inc. (NASDAQ: GALT). ...
Dec 14, 2017 09:30 am ET
Galectin Therapeutics Provides Corporate Update at Annual Meeting
Dr. Peter Traber, CEO and CMO, reviews results of NASH-CX trial that demonstrated statistically significant and clinically meaningful effects in patients who had NASH cirrhosis but did not have esophageal varices
Dec 11, 2017 09:00 am ET
Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate update via live webcast immediately following the business...
Dec 05, 2017 08:15 am ET
Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02
Dec 04, 2017 04:00 pm ET
Dec 01, 2017 08:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Xilinx, J.B. Hunt Transport Services, Southern, FirstEnergy, AMAG Pharmaceuticals, and Galectin Therapeutics — New Research Emphasiz
NEW YORK, Dec. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Xilinx, Inc. (NASDAQ:XLNX), J.B. Hunt...
Nov 13, 2017 09:00 am ET
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D., the Company's chief executive officer and chief medical officer, has been named the...
Nov 07, 2017 08:15 am ET
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be announced in early December 2017
Aug 14, 2017 08:15 am ET
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended June 30, 2017. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov....
Jul 25, 2017 08:30 am ET
Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
NORCROSS, Ga., July 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Method of Enhancing Specific Immunotherapies in Cancer Treatment." Cancer immunotherapy research conducted by Dr. William Redmond at the Earle A. Chiles Research Institute at the Providence Cancer Center in Portland, Oregon was instrumental in the allowance of this patent. Members of Galectin and Providence are joint inventors on the patent, and ...
Jun 29, 2017 09:02 am ET
Ammo, Inc. Appoints Two Senior Executives to Board of Directors
SCOTTSDALE, Ariz., June 29, 2017 (GLOBE NEWSWIRE) -- AMMO, Inc. (OTC:POWW), a premier American ammunitions developer, manufacturer and distributor, today announced it has appointed two highly accomplished, senior business executives to its Board of Directors: Russell William “Rusty” Wallace, Jr., and James C. Czirr....
May 15, 2017 08:30 am ET
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
NORCROSS, Ga., May 15, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2017. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov....
May 03, 2017 08:30 am ET
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver Line, an online community and publication on liver health and liver disease....
Apr 18, 2017 08:00 am ET
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the presentation of a late-breaking abstract at The International Liver Congress™ 2017. The data demonstrates the effectiveness of the Exalenz 13C-Methacetin Breath Test (MBT) as a non-invasive test of liver function....
Mar 06, 2017 08:30 am ET
Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period...
Feb 07, 2017 04:40 pm ET
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical TrialsNORCROSS, Ga., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Providence Cancer Center today announced the presentation of preclinical and early clinical data from two investigator-initiated Phase 1 clinical trials of GR-MD-02 used in combination with approved cancer immunotherapies. Data presented today at the 9th GTCBio Immunotherapeutics &a...
Feb 06, 2017 08:30 am ET
Galectin Therapeutics Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation...
Feb 06, 2017 08:30 am ET
Galectin Therapeutics Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation...
Feb 01, 2017 08:10 am ET
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December 2017. ...
Jan 30, 2017 02:16 pm ET
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd
 CEOs & CFOs share vision, answer questions live at VirtualInvestorsConferences.com ...
Jan 30, 2017 02:16 pm ET
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd
 CEOs & CFOs share vision, answer questions live at VirtualInvestorsConferences.com ...
Jan 30, 2017 08:30 am ET
Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2
The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com...
Jan 30, 2017 08:30 am ET
Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2
The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com...
Oct 17, 2016 08:30 am ET
Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia
NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the company's president, chief executive officer and chief medical officer, will present at The MicroCap Conference on Tuesday, October 25, 2016 at 8:30 a.m. ET. The conference is being held in Philadelphia, Pennsylvania at the Hotel Monaco....
Sep 27, 2016 04:15 pm ET
Aug 31, 2016 08:00 am ET
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company's president, chief executive officer and chief medical officer, will present at Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 3:50 p.m. Eastern time. The conference is being held at the New York Palace Hotel in New York City on September 11-13, 2016....
Aug 25, 2016 08:00 am ET
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
NORCROSS, Ga., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis....
Aug 09, 2016 08:00 am ET
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September...
Aug 02, 2016 08:45 am ET
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis (the NASH-CX trial).  The Company expects to report the topline results of this trial in December 2017, as previously planned....
Jun 02, 2016 08:00 am ET
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension
NORCROSS, Ga., June 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular remodeling in an animal model of pulmonary arterial hypertension (PAH). The results were presented at the American Thoracic Society (ATS) 2016 International Conference by investigators from the Vascular Biology Center and the Department of Pharmacology and Toxicology at Augusta University (...
May 16, 2016 04:05 pm ET
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis
A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks...
May 11, 2016 08:00 am ET
Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis
NORCROSS, Ga., May 11, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the completion of enrollment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3) (the NASH-FX trial).  The Company expects to report the top line results of this trial by the end of September 2016, as previously planned....
May 10, 2016 08:00 am ET
Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
NORCROSS, Ga., May 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2016. These results are included in the Company’s Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov....
May 05, 2016 08:00 am ET
Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference
NORCROSS, Ga., May 05, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has received notification that its collaborative abstract with investigators at Augusta University “Galectin-3 Mediates Vascular Remodeling in Pulmonary Arterial Hypertension” has been accepted for presentation at the American Thoracic Society (ATS) 2016 International Conference, taking place May 13-18 in San Francisco....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.